IP Library Granted Patent US 9,737,483
Granted Patent B2
US 9,737,483 · App. 13/787,117 · Granted Aug 22, 2017

Method for formulating large diameter synthetic membrane vesicles

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,737,483
App. No.
13/787,117
Granted
Aug 22, 2017
Kind
B2
Abstract

The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Claims (50)

1. A process for making an emulsion using a continuous-flow emulsification system, wherein said emulsification system comprises:

a high shear mixer, comprised of a rotor and a stator;

a recirculation loop, comprised of one or more recirculation lines and an exit line;

a heat exchanger;

one or more outlet lines, comprised of at least one nozzle feed line;

one or more continuous phase inlet lines; and

a discontinuous phase inlet line;

wherein the heat exchanger and the high shear mixer are connected together in the recirculation loop by the one or more recirculation lines, wherein an end of one of the one or more recirculation lines connects to an inlet of the high shear mixer and an end of the exit line connects to an outlet of the high shear mixer;

further wherein the one or more outlet lines and one or more continuous phase inlet lines are connected to the recirculation loop, wherein at least one of the one or more continuous phase inlet lines is directly connected to the one of the one or more recirculation lines and the at least one nozzle feed line is directly connected to the exit line;

further wherein the end of the discontinuous phase inlet line is located less than ⅓ rd of a rotor diameter from the rotor and less than ⅓ rd of a rotor diameter from the rotation axis of the rotor and is in fluid communication with the rotor, said process comprising:

feeding an organic discontinuous phase into the emulsification system through the discontinuous phase inlet line and feeding an aqueous continuous phase into the emulsification system through one or more continuous phase inlet lines.

2. The process of claim 1 , wherein the organic discontinuous phase comprises a triglyceride.

3. The process of claim 1 , wherein the emulsion comprises a triglyceride, surfactant, and water.

4. The process of claim 1 further comprising:

passing the organic discontinuous phase through a hydrophobic sterilizing filter before feeding the aqueous discontinuous phase into the emulsification system through the discontinuous phase inlet line; and

passing the aqueous continuous phase through a hydrophilic sterilizing filter before feeding the organic continuous phase into the emulsification system through the one or more continuous phase inlet lines.

5. A process for making an emulsion using a continuous-flow emulsification system, wherein said emulsification system comprises:

a high shear mixer, comprised of a rotor and a stator;

a recirculation loop, comprised of one or more recirculation lines and an exit line;

a heat exchanger;

one or more outlet lines, comprised of at least one nozzle feed line;

one or more continuous phase inlet lines; and

a discontinuous phase inlet line;

wherein the heat exchanger and the high shear mixer are connected together in the recirculation loop by the one or more recirculation lines, wherein an end of one of the one or more recirculation lines connects to an inlet of the high shear mixer and an end of the exit line connects to an outlet of the high shear mixer;

further wherein the one or more outlet lines and one or more continuous phase inlet lines are connected to the recirculation loop, wherein at least one of the one or more continuous phase inlet lines is directly connected to the one of the one or more recirculation lines and the at least one nozzle feed line is directly connected to the exit line;

further wherein the end of the discontinuous phase inlet line is located less than ⅓ rd of a rotor diameter from the rotor and less than ⅓ rd of a rotor diameter from the rotation axis of the rotor and is in fluid communication with the rotor, said process comprising:

feeding an aqueous discontinuous phase into the emulsification system through the discontinuous phase inlet line and feeding an organic continuous phase into the emulsification system through the one or more continuous phase inlet lines.

6. The process of claim 5 , wherein the organic continuous phase comprises an organic solvent and a neutral lipid.

7. The process of claim 6 , wherein the organic solvent is methylene chloride or chloroform.

8. The process of claim 5 wherein the aqueous discontinuous phase comprises an acid and a therapeutic agent.

9. The process of claim 8 , wherein the acid is phosphoric acid.

10. The process of claim 8 , wherein the therapeutic agent is bupivacaine.

11. The process of claim 5 , wherein a portion of the emulsion is fed through the at least one nozzle feed line to a first fluid conduit of at least one atomizing nozzle apparatus, wherein said at least one atomizing nozzle apparatus comprises:

the first fluid conduit and a second fluid conduit each having at least one entrance orifice and at least one exit orifice;

a fluid contacting chamber having a top comprising at least one entrance orifice connecting to the at least one exit orifice of the first fluid conduit and having a bottom comprising at least one exit orifice, wherein the at least one exit orifice of the second fluid conduit connects to the top of the fluid contacting chamber; and

a third fluid conduit, wherein the third fluid conduit annularly surrounds a portion of the fluid contacting chamber.

12. The process of claim 11 , wherein the process further comprises applying a second aqueous phase to the second fluid conduit; and applying a gas to the third fluid conduit.

13. The process of claim 11 , wherein between 50% and 99.99% of the emulsion exiting the high shear mixer is passed through the heat exchanger.

14. The process of claim 11 , wherein between 80% and 99.99% of the emulsion exiting the high shear mixer is passed through the heat exchanger.

15. The process of claim 11 , wherein between 1 mL/minute and 8,000 mL/minute of the emulsion exiting the high shear mixer is fed through the at least one nozzle feed line to the first fluid conduit of the at least one atomizing nozzle apparatus.

16. The process of claim 11 , wherein between 40 mL/minute and 100 mL/minute of the emulsion exiting the high shear mixer is fed through the at least one nozzle feed line to the first fluid conduit of the at least one atomizing nozzle apparatus.

17. The process of claim 11 further comprising:

providing the portion of the emulsion traveling to the at least one atomizing nozzle apparatus through the at least one nozzle feed line at a flow rate that is equal to a sum of the flow rate of the organic continuous phase through the one or more organic phase inlet lines and the flow rate of the aqueous discontinuous phase through the discontinuous phase inlet line.

18. The process of claim 5 , further comprising forming emulsion droplets which are on average less than 10 microns in diameter.

19. The process of claim 5 , wherein a length of one of the one or more recirculation lines annularly surrounds a length of the discontinuous phase inlet line.

20. The process of claim 5 , wherein the organic continuous phase comprises a triglyceride.

21. The process of claim 5 , wherein the emulsion comprises a triglyceride, surfactant, and water.

22. The process of claim 5 further comprising:

passing the aqueous discontinuous phase through a hydrophilic sterilizing filter before feeding the aqueous discontinuous phase into the emulsification system through the discontinuous phase inlet line; and

passing the organic continuous phase through a hydrophobic sterilizing filter before feeding the organic continuous phase into the emulsification system through the one or more continuous phase inlet lines.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2025
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 073779/0532 →
SECURITY INTEREST Recorded Jul 4, 2025
From: PACIRA PHARMACEUTICALS, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 071814/0792 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 31, 2023
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 063213/0864 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 31, 2023
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 063214/0108 →
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Dec 14, 2021
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; FLEXION THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 058516/0636 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2015
From: SCHUTT, ERNEST GEORGE; MCGUIRE, RONALD WARREN; WALTERS, PETER ANDREW; LOS, KATHLEEN D.A.
To: PACIRA PHARMACEUTICALS, INC.
Reel/Frame 037077/0554 →